Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
IPO Year:
Exchange: NYSE
Website: taro.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/18/2024 | $43.00 | Buy → Neutral | H.C. Wainwright |
| 1/31/2022 | $75.00 → $73.00 | Buy | HC Wainwright & Co. |
| 1/18/2022 | $82.00 → $75.00 | Buy | HC Wainwright & Co. |
| 7/28/2021 | $80.00 → $82.00 | Buy | HC Wainwright & Co. |
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") today announced the appointment of William J. Coote as Vice President, Chief Financial Officer and Chief Accounting Officer, effective today. Mr. Coote has over 25 years of significant financial executive experience; most recently serving as Taro's AVP, Treasurer and Business Finance since 2008. Prior to joining Taro, Mr. Coote has held progressively responsible positions with a variety of global companies such as Bowne & Co., Prudential Realty, Merrill Lynch, and Ernst & Young. Throughout his career, he has been accountable for areas such as: Accounting, Treasury, Budgeting, Financial Planning and Analysis, Acquisitions, Investor R
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue other opportunities. Mr. Uday Baldota, Taro's CEO, stated, "On behalf of the Company, I want to thank Daphne for her valuable contributions including her efforts over the past year during the COVID-19 pandemic. We wish her the best in her future endeavors." The Company has initiated a search for a successor as Chief Financial Officer. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, de
15F-12B - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)
25-NSE - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
6-K - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)
SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
6-K - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)
6-K - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)
SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
H.C. Wainwright downgraded Taro Pharm from Buy to Neutral and set a new price target of $43.00
HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $73.00 from $75.00 previously
HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $75.00 from $82.00 previously
HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $82.00 from $80.00 previously
HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $80.00 from $81.00 previously
HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $81.00 from $80.00 previously
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.31 by 38.71 percent. The company reported quarterly sales of $164.941 million which beat the analyst consensus estimate of $156.062 million by 5.69 percent. This is a 12.52 percent increase over sales of $146.587 million the same period last year.
Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd. Dear Linda, As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Krensavage Asset Management LLC remains opposed to Sun Pharmaceutical Industries Ltd.'s inadequate bid to take Taro private.
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.30 by 80 percent. The company reported quarterly sales of $157.10 million which beat the analyst consensus estimate of $154.91 million by 1.42 percent. This is a 12.86 percent increase over sales of $139.20 million the same period last year.
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly sales of $157.10 million which beat the analyst consensus estimate of $154.91 million by 1.42 percent. This is a 12.86 percent increase over sales of $139.20 million the same period last year.
Companies Reporting Before The Bell • Nokia (NYSE:NOK) is projected to report quarterly earnings at $0.15 per share on revenue of $7.05 billion. • Popular (NASDAQ:BPOP) is likely to report quarterly earnings at $1.61 per share on revenue of $538.72 million. • Carpenter Tech (NYSE:CRS) is estimated to report quarterly earnings at $0.85 per share on revenue of $657.10 million. • Berkshire Hills Bancorp (NYSE:BHLB) is estimated to report quarterly earnings at $0.49 per share on revenue of $94.52 million. • NetScout Systems (NASDAQ:NTCT) is projected to report quarterly earnings at $0.37 per share on revenue of $198.38 million. • NextEra Energy (NYSE:NEE) is expected to report quarterly ea
Taro Pharmaceutical Indus (NYSE:TARO) is set to give its latest quarterly earnings report on Thursday, 2024-01-25. Here's what investors need to know before the announcement. Analysts estimate that Taro Pharmaceutical Indus will report an earnings per share (EPS) of $0.30. Taro Pharmaceutical Indus bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.20, which was foll
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Taro Pharmaceutical Indus (NYSE:TARO) from Buy to Neutral and maintains the price target from $43 to $43.
Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.18 by 111.11 percent. This is a 42.42 percent decrease over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $148.20 million which missed the analyst consensus estimate of $161.14 million by 8.03 percent. This is a 13.57 percent increase over sales of $130.50 million the same period last year.
Combined entity is better positioned to compete in increasingly competitive generics industry MUMBAI, India and PRINCETON, N.J., June 24, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") with its subsidiary. As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro is now a private company and wholly-own
MUMBAI, India and NEW YORK, May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024. The details of the merger agreement were announced on January 17, 2024.
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to March 31, 2023 Net sales of $164.9 million increased $18.4 million, or 12.5%, principally due to new launches and gross-to-net ("GTN") adjustments. Excluding the impact of GTN adjustments, sales growth was high single digits. Gross profit of $87.4 million (53.0% of net sales) compared to $75.7 million (51.6% of net sales). Research and development (R&D) expenses of $20.5 million increased $4.2 million. Selling, marketing, general and administrative expenses (SG&A
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2024, after the close of market on Monday, May 20, 2024. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.com: https://www.busi
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis & Co. ("Glass Lewis") have both recommended that Taro shareholders vote "FOR" the pending Merger transaction with Sun Pharmaceutical Industries Ltd. ("Sun Pharma") at the upcoming May 22, 2024, extraordinary general meeting of shareholders. Taro's shareholders are reminded that the May 19, 2024, deadline for proxy voting is rapidly approaching and are urged to vote "FOR" the transaction, as unanimously recommended by Taro's Special Committee, Board of Directors, Audit Committee and both proxy advi
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that it has called an extraordinary general meeting of its shareholders (the "Extraordinary General Meeting"), to be held on May 22, 2024, at 10:00 a.m., Israel time, and a class meeting (the "Ordinary Class Meeting" and together with the Extraordinary General Meeting, the "Meetings") of the holders of the Company's ordinary shares (the "Ordinary Shares"), to be held on May 22, 2024, at 11:00 a.m., Israel time, or immediately after the conclusion of the Extraordinary General Meeting, whichever is later, at Meitar Law Offices located at 16 Abba Hillel Road, 10th Floor, Ramat Gan, Israel. Following the O
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd. Krensavage Asset Management LLC610 Fifth AvenueSuite 301New York, NY [email protected] Taro Special CommitteeLinda [email protected] Dear Linda, As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Krensavage Asset Management LLC remains opposed to Sun Pharmaceutical Industries Ltd.'s inadequate bid to take Taro private. Since we expressed our dismay in an open letter July 19, Sun, a 78.5% Taro shareholder, hiked its bid 13
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and nine months ended December 31, 2023. Quarter ended December 31, 2023 Highlights ─ compared to December 31, 2022 Net sales of $157.1 million increased $17.9 million or 12.9% principally due to new launches and gross-to-net ("GTN") adjustments. Excluding the impact of GTN adjustments, sales growth was high single digits. Gross profit of $79.9 million (50.8% of net sales) compared to $64.0 million (46.0% of net sales). Research and development (R&D) expenses of $13.6 million increased $0.7 million. Selling, marketing, general and administrative
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswir
Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023 MUMBAI, India and NEW YORK, Jan. 17, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro's controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in
SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswir
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businessw
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.com: h
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.com
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022, after the close of market on Thursday, October 27, 2022. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.c
Galderma: Continued strong commercial and financial performance in a resilient market Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD Particularly strong performance of Injectable Aesthetics and Dermo-cosmetics product categories with growth of 32% and 31% on a constant currency basis, respectively Volume as a primary growth driver underpins confidence in the resilience and long-term growth fundamentals of the dermatology market On track to deliver on 2022 guidance of 12-14% net sales and core EBITDA growth on a constant currency basis Advancing innovation across its leading derma
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.com: htt